1184 related articles for article (PubMed ID: 32436994)
1. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
6. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
8. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
[TBL] [Abstract][Full Text] [Related]
10. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
11. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
Quartuccio L; Sonaglia A; Pecori D; Peghin M; Fabris M; Tascini C; De Vita S
J Med Virol; 2020 Nov; 92(11):2852-2856. PubMed ID: 32515499
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
Knorr JP; Colomy V; Mauriello CM; Ha S
J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
17. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
19. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
Zhou Z; Price CC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1407-1412. PubMed ID: 33094669
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
